Clinical Trial Update: Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating BeneFIX and a new BeneFIX formulation (rFIX-R) in moderate to severe Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)
• rFIX-R (recombinant human coagulation factor IX)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED